QQCWB

GV

Translating P53 Into The Clinic

Di: Ava

亲爱的研友该休息了！由于当前在线用户较少，发布求助请尽量完整地填写文献信息，科研通机器人24小时在线，伴您度过漫漫科研夜！身体可是革命的本钱，早点休息，好梦！ This communication focuses on the transfer of some of the hard won information about the p53 protein, its mutations, structures, and activities learned in the basic science laboratory and translated to the clinic. ©2022 The Authors; Published by the American Association for Cancer Research. To our knowledge, this paper presents the first example of mutant p53 restoration by a low-molecular-weight compound, which later made its way into clinical trials, albeit with limited success.

Translating p53 into the clinic Chit Fang Cheok, Chandra S. Verma, José Baselga and David P. Lane 请遵守相关知识产权规定，勿将文件分享给他人，仅可用于个人研究学习 科研通，让源源不断科研创作灵感的涌现之地

It is only recently that drugs targeting K-RAS and Tp53 missense mutations have been developed, and along with the allele specific nature of some of these drugs comes the possibility of combining them with the immunologic therapies for cancers. It Translating p53 into the clinic C. F. CheokC. VermaJ. BaselgaD. Lane Medicine Nature Reviews Clinical Oncology 2010 TLDR The first agent found to restore the active function of mutant TP53 has just entered the clinic and the basis of these trials and the future of p53-based therapy is discussed. Expand 364 已入深夜，您辛苦了！由于当前在线用户较少，发布求助请尽量完整的填写文献信息，科研通机器人24小时在线，伴您度过漫漫科研夜！祝你早点完成任务，早点休息，好梦！ 已完结 文献求助详情 标题 Translating p53-based therapies for cancer into the clinic 将基于p53的癌症治疗转化为临床 相关领域 MDMX公司

Translating p53 into the clinic

清晨好，您是今天最早来到科研通的研友！由于当前在线用户较少，发布求助请尽量完整的填写文献信息，科研通机器人24小时在线，伴您科研之路漫漫前行！ 已完结 文献求助详情 标题 Translating p53-based therapies for cancer into the clinic 将基于p53的癌症治疗转化为临床 相关领域 MDMX公司 平方毫米 抑制器 已入深夜，您辛苦了！由于当前在线用户较少，发布求助请尽量完整的填写文献信息，科研通机器人24小时在线，伴您度过漫漫科研夜！祝你早点完成任务，早点休息，好梦！ 标题 Translating p53-based therapies for cancer into the clinic 将基于p53的癌症治疗转化为临床 相关领域 MDMX公司 平方毫米 抑制器 突变体 亲爱的研友该休息了！由于当前在线用户较少，发布求助请尽量完整的填写文献信息，科研通机器人24小时在线，伴您度过漫漫科研夜！身体可是革命的本钱，早点休息，好梦！

We read with interest the Review by Peuget et al. (Peuget, S., Zhou, X. & Selivanova, G. Translating p53-based therapies for cancer into the clinic. Nat. Rev. Cancer 24, 192–215 (2024)) 1 that Translating p53-based therapies for cancer into the clinic MDMX公司 平方毫米 抑制器 突变体 生物 癌症研究 癌症 转录因子 野生型 基因 抑癌基因 癌变 遗传学 作者 Sylvain Peuget, Xiaolei Zhou, Galina Selivanova

Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and

请遵守相关知识产权规定，勿将文件分享给他人，仅可用于个人研究学习

Pharmacological Activation of p53 in Cancer Cells

已经有人上传了文献，该状态下其他人无法上传，请等待求助人确认该文件是否是他需要的。 如果求助人在 48 小时内还未确认，系统默认应助成功，本求助将自动关闭。 2024年1月29日，瑞典卡罗林斯卡医学院的Galina Selivanova等人在国际知名期刊Nat Rev Cancer上发表了一篇 “Translating p53-based

Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and

Although p53 was once considered undruggable, in this Review, Peuget et al. discuss the progress made in targeting p53 as a form of cancer therapy with approaches ranging from restoration of mutant p53 function to inhibition of the negative regulator of p53, MDM2, as well as newer strategies, including p53-based mRNA vaccines and In summary, the major strategies for translating p53 research into the clinic to treat cancer have been focused on developing small molecules that may target mutant p53 and refold it to its wild-type conformation or target molecules that eventually may lead to 亲爱的研友该休息了！由于当前在线用户较少，发布求助请尽量完整的填写文献信息，科研通机器人24小时在线，伴您度过漫漫科研夜！身体可是革命的本钱，早点休息，好梦！

Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and

In addition, approaches to deplete mutant p53 or to target vulnerabilities created by mutant p53 expression are currently under development. In wild-type p53 tumours, the major approach is to protect p53 from the actions of MDM2 and MDMX by Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and metastasis in

Translating p53-based therapies for cancer into the clinic

关注科研痛点，打通你的七经六脉 科研通，让源源不断科研创作灵感的涌现之地 Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and

Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and Translating p53-based therapies for cancer into the clinic MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation Data from Decreased DNA Damage and Improved p53 Specificity of RITA Analogs Inhibition of p53 inhibitors: progress, challenges and perspectives

Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and To gain further insight into the clinical utility of NRs, the authors established a patient-derived xenograft model from an ovarian tumour that expressed mutant p53. over 13 days, NRs–pt

This bionic peptide nanodrug E@MDP effectively targets intracellular MDM2/MDMX, alleviates their negative regulatory effects on p53, and promotes the reaccumulation of p53 within lung adenocarcinoma cells. It exerts anti-tumor effects while synergistically enhancing the efficacy of PD-1 inhibitor immunotherapy (Figure 1).

Translating p53 into the clinic.

Inhibitors of MDM2 and MDMX: A Structural Perspective Peptide Activators of the p53 Tumor Suppressor Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axis Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and Abstract： Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all, human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms: mutation of th

In addition, approaches to deplete mutant p53 or to target vulnerabilities created by mutant p53 expression are currently under development. In wild-type p53 tumours, the major approach is to protect p53 from the actions of MDM2 and MDMX by

亲爱的研友该休息了！由于当前在线用户较少，发布求助请尽量完整地填写文献信息，科研通机器人24小时在线，伴您度过漫漫科研夜！身体可是革命的本钱，早点休息，好梦！